All In Biotech

Drug Trial Radar · NCT07758101

A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injection or Intravenous Infusion of SHR-7590 Injection in Healthy Chinese Participants and Participants With Moderate-to-Severe Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Aug 21, 2026

Primary completion

Mar 31, 2028

Study completion Apr 28, 2029

Sponsor

Sponsor type
Industry
First posted
Aug 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase I first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-7590 via subcutaneous or intravenous administration in Chinese healthy participants and patients with moderate-to-severe inflammatory bowel disease.

Conditions

  • Moderate-to-severe Inflammatory Bowel Disease

Interventions

  • SHR-7590Drug

    SHR-7590

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part1: Adverse eventsTime frame: From ICF signing date to Day 281
  2. Part1: Serious adverse eventsTime frame: From ICF signing date to Day 281
  3. Part2: Adverse eventsTime frame: From ICF signing date to Day 393
  4. Part2: Serious adverse eventsTime frame: From ICF signing date to Day 393
  5. Part2: Results of 12-lead electrocardiographyTime frame: From ICF signing date to Day 393

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangzhou, China · Recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.